Project Management: ISAResearch Centre | Deutsches Herzzentrum, Munich, Germany
Contributing Countries: US | Switzerland | France | Germany | Belgium | Denmark | Italy | Latvia
The COBRA PzF NanoCoated Coronary Stent is not currently approved or indicated for high bleeding risk patients with 14-day DAPT.
2016 ACC/AHA Guidelines for Duration of DAPT in Patients with Coronary Artery Disease
Indications, Contraindications, Warnings & Precautions
*Patients on Oral Anticoagulants
‡Data presented reflects six-month follow-up data available as of October 15, 2020. Six-month follow-up data for N = 15 patients is pending. Readers should be aware that any aspect of the research, including the results and conclusions, may change as a result of the pending data and subsequent peer review.
- Byrne R. Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy (COBRA-REDUCE). Presented at: TCT 2020; October 15, 2020
- Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019;40(31):2632-2653.
- Généreux P, Giustino G, Witzenbichler B, et al. Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2015;66(9):1036-1045.